Amit Sachdev Sells 58,613 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 58,613 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $468.83, for a total transaction of $27,479,532.79. Following the completion of the transaction, the executive vice president owned 58,934 shares in the company, valued at approximately $27,630,027.22. The trade was a 49.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amit Sachdev also recently made the following trade(s):

• On Wednesday, February 25th, Amit Sachdev sold 1,846 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $486.35, for a total transaction of $897,802.10.

Vertex Pharmaceuticals Trading Up 3.5%

Shares of NASDAQ:VRTX opened at $496.83 on Friday. The stock has a market capitalization of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.30. The stock’s 50-day moving average price is $466.55 and its 200-day moving average price is $432.29. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. During the same quarter in the prior year, the company earned $3.98 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new stake in Vertex Pharmaceuticals in the second quarter worth $1,593,974,000. Capital International Investors boosted its holdings in shares of Vertex Pharmaceuticals by 77.9% during the 3rd quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company’s stock valued at $1,836,550,000 after buying an additional 2,053,156 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Vertex Pharmaceuticals by 49.4% in the 4th quarter. Victory Capital Management Inc. now owns 3,356,766 shares of the pharmaceutical company’s stock worth $1,521,851,000 after buying an additional 1,109,200 shares during the period. Capital Research Global Investors grew its position in shares of Vertex Pharmaceuticals by 4.6% in the 4th quarter. Capital Research Global Investors now owns 17,316,344 shares of the pharmaceutical company’s stock worth $7,850,544,000 after buying an additional 763,063 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Vertex Pharmaceuticals by 214.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 763,703 shares of the pharmaceutical company’s stock worth $299,097,000 after acquiring an additional 520,949 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VRTX shares. Leerink Partners lifted their target price on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an “outperform” rating in a research note on Monday, December 29th. Morgan Stanley reaffirmed an “overweight” rating and set a $570.00 price objective on shares of Vertex Pharmaceuticals in a research note on Friday, February 13th. Scotiabank increased their target price on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a report on Friday, February 13th. Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 price target on the stock in a report on Friday, February 13th. Finally, Barclays upped their price target on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an “overweight” rating in a research report on Tuesday, February 17th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $542.00.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.